Diamantopoulos, P.T.; Kontandreopoulou, C.-N.; Gkoufa, A.; Solomou, E.; Anastasopoulou, A.; Palli, E.; Kouzis, P.; Bouros, S.; Samarkos, M.; Magiorkinis, G.;
et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy. Cancers 2022, 14, 3791.
https://doi.org/10.3390/cancers14153791
AMA Style
Diamantopoulos PT, Kontandreopoulou C-N, Gkoufa A, Solomou E, Anastasopoulou A, Palli E, Kouzis P, Bouros S, Samarkos M, Magiorkinis G,
et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy. Cancers. 2022; 14(15):3791.
https://doi.org/10.3390/cancers14153791
Chicago/Turabian Style
Diamantopoulos, Panagiotis T., Christina-Nefeli Kontandreopoulou, Aikaterini Gkoufa, Elena Solomou, Amalia Anastasopoulou, Eleni Palli, Panagiotis Kouzis, Spyros Bouros, Mihalis Samarkos, Gkikas Magiorkinis,
and et al. 2022. "Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy" Cancers 14, no. 15: 3791.
https://doi.org/10.3390/cancers14153791
APA Style
Diamantopoulos, P. T., Kontandreopoulou, C. -N., Gkoufa, A., Solomou, E., Anastasopoulou, A., Palli, E., Kouzis, P., Bouros, S., Samarkos, M., Magiorkinis, G., & Gogas, H.
(2022). Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy. Cancers, 14(15), 3791.
https://doi.org/10.3390/cancers14153791
